Compare CHMI & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | CSBR |
|---|---|---|
| Founded | 2012 | 1985 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.9M | 82.7M |
| IPO Year | N/A | 2015 |
| Metric | CHMI | CSBR |
|---|---|---|
| Price | $2.65 | $5.50 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 144.2K | 4.9K |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | ★ 15.09% | N/A |
| EPS Growth | N/A | ★ 161.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,900,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | $31.73 | $11.51 |
| P/E Ratio | $139.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $5.59 |
| 52 Week High | $3.67 | $10.25 |
| Indicator | CHMI | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 51.61 | 49.92 |
| Support Level | $2.50 | $5.59 |
| Resistance Level | $2.74 | $6.24 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 50.18 | 81.08 |
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.